Volume 6, Number 4

The Management of Fatigue in Depressed Patients
It is estimated that only 1 patient out of 5 who respond to new-generation antidepressants is actually symptom free, and three quarters of patients being treated for depression still report fatigue, which is the most common predictor of depression. Read More

Genetics and Psychopharmacology: Prospects for Individualized Treatment
Genetic factors affect the many aspects of the response to psychopharmacologic agents. This article provides a clean and succinct description of the components of inheritance, such as trait, transmission, genetic variability, and gene interaction. Read More

Augmentation of Standard Antidepressants With Atypical Antipsychotic Agents for Treatment-resistant Major Depressive Disorder
Between 29% and 46% of patients with depression fail to recover fully with antidepressant therapy, leading the practitioner no choice but to view the patients condition diagnostically as well as from an emotional and psychopathological vantage point. Read More

Special Report
Study Designs and Outcomes in Antidepressant Clinical Trials
Ironically, there has been a failure to demonstrate the therapeutic effectiveness of the newer antidepressants, not because they do not work--we know they do--but because of an increased response to placebo. Read More

Interview
Long-term Benefits of Early Pharmacologic Treatment in Alzheimer's Disease
A timely interview discusses the steady increase in the size of the population with Alzheimer's disease and the regular introduction of new drugs that help ameliorate the nightmare that this condition represents for patients and their families. Read More